Systemic sclerosis & Raynaud's
Teclistamab for treatment-refractory autoimmune diseases: a multicentre case series
Authors' conclusion
Teclistamab demonstrated the potential to induce treatment-free responses in refractory autoimmune disease, but clinically relevant safety events, including infections and fatal outcomes in patients with advanced cardiac involvement, highlight the need for careful patient selection and monitoring.
Study context
- Population
- Patients with treatment-refractory systemic sclerosis (SSc), IIM, systemic lupus erythematosus (SLE), undifferentiated connective tissue disease (UCTD) or IgG4-related disease (IgG4-RD) (72% women, median age 48.5 years; median 5 prior therapies)10 SSc, 4 IIM, 2 SLE, 1 UCTD, 1 IgG4-RD
- Participants
- 18 patients
- Outcome
- Clinical response
- Follow-up
- Median 5.1 months (range, 0.8-21.2 months)
Methodological detailsmulticentre, 5 European centres, Data retrospectively collected; median cumulative dose 6.36 mg/kg teclistamab
- Multicentre
- 5 European centres
- Data retrospectively collected; median cumulative dose 6.36 mg/kg teclistamab
Main finding
As reported in the abstract
| Group | Value | Minimal-to-moderate responses |
|---|---|---|
| Teclistamab | 61% | 4 (22%) |
Teclistamab
Value61%
Minimal-to-moderate responses4 (22%)
- Major clinical responses despite discontinuation of immunosuppressive therapy
- 11 (61%)
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Deaths | Teclistamab 2 events |
- Deaths: patients with severe SSc-associated cardiac involvement; 1 sudden cardiac death, 1 after diffuse alveolar haemorrhage and HF
B-cell depletion and autoantibody levels
- B-cell depletion observed in all patients, with significant reductions in autoantibody levels
Deaths
- Deaths in patients with severe SSc-associated cardiac involvement (1 sudden cardiac death; 1 after diffuse alveolar haemorrhage and HF)
- 2
Safety
Cytokine release syndrome
- Patients with cytokine release syndrome
- 12 (67%)
- Cytokine release syndrome episodes (16 grade 1 and 6 grade 2)
- 22
Severe hypogammaglobulinaemia
- All patients developed severe hypogammaglobulinaemia
Severe infections
- Patients with severe infections
- 5 (28%)
IBD-like colitis
- Patients with inflammatory bowel disease-like colitis
- 2
Original publication
Teclistamab for treatment-refractory autoimmune diseases: a multicentre case series. Ann Rheum Dis. Published 19 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →